Wall Street analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to announce sales of $3.90 million for the current quarter, according to Zacks. Four analysts have made estimates for Assembly Biosciences’ earnings. The highest sales estimate is $4.00 million and the lowest is $3.70 million. Assembly Biosciences reported sales of $3.22 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 21.1%. The business is expected to announce its next quarterly earnings report on Wednesday, August 14th.
On average, analysts expect that Assembly Biosciences will report full-year sales of $15.11 million for the current fiscal year, with estimates ranging from $14.00 million to $15.89 million. For the next fiscal year, analysts forecast that the company will report sales of $15.51 million, with estimates ranging from $14.00 million to $16.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.06) by $0.01. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. The firm had revenue of $3.89 million for the quarter, compared to analyst estimates of $3.81 million.
ASMB has been the subject of several research analyst reports. William Blair reissued a “buy” rating on shares of Assembly Biosciences in a research note on Tuesday, July 16th. Chardan Capital restated a “hold” rating on shares of Assembly Biosciences in a report on Sunday, June 30th. Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. Finally, BidaskClub cut Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a report on Monday, June 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. Assembly Biosciences presently has a consensus rating of “Hold” and an average price target of $41.20.
Institutional investors have recently bought and sold shares of the business. Deutsche Bank AG boosted its holdings in shares of Assembly Biosciences by 29.8% during the 4th quarter. Deutsche Bank AG now owns 54,606 shares of the biopharmaceutical company’s stock worth $1,234,000 after buying an additional 12,525 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in shares of Assembly Biosciences by 15.3% in the 4th quarter. New York State Common Retirement Fund now owns 23,300 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 3,100 shares in the last quarter. Tibra Equities Europe Ltd bought a new position in shares of Assembly Biosciences in the 1st quarter worth $918,000. Emerald Mutual Fund Advisers Trust lifted its holdings in shares of Assembly Biosciences by 13.3% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 418,143 shares of the biopharmaceutical company’s stock worth $8,233,000 after purchasing an additional 49,230 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Assembly Biosciences by 136.0% in the 4th quarter. FMR LLC now owns 443,036 shares of the biopharmaceutical company’s stock worth $10,021,000 after purchasing an additional 255,336 shares in the last quarter. Hedge funds and other institutional investors own 86.44% of the company’s stock.
ASMB stock traded down $0.97 during midday trading on Friday, reaching $13.00. 213,042 shares of the company were exchanged, compared to its average volume of 357,036. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.97 and a quick ratio of 7.97. The stock’s 50-day simple moving average is $14.11. Assembly Biosciences has a one year low of $12.75 and a one year high of $44.65. The firm has a market capitalization of $332.15 million, a price-to-earnings ratio of -3.27 and a beta of 1.46.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Further Reading: How much money do you need to begin day trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.